Home » U.S. High Court Ruling on Isolated DNA Patentability Is Blow to Biotech Firms
U.S. High Court Ruling on Isolated DNA Patentability Is Blow to Biotech Firms
July 2, 2013
The U.S. Supreme Court June 13 dismissed Myriad Genetics’ patent-eligibility claims on the BRCA1 and BRCA2 genes commonly associated with breast and ovarian cancers, while upholding the company’s patents on the diagnostic technology it created from those genes.
To View This Article:
Subscribe To International Medical Device Regulatory Monitor